Zobrazeno 1 - 10
of 75
pro vyhledávání: '"Ming-Mo Hou"'
Autor:
Shuen-Iu Hung, Mu-Tzu Chu, Ming-Mo Hou, Yun-Shien Lee, Chan-Keng Yang, Sung-Yu Chu, Feng-Yuan Liu, Hung-Chih Hsu, Shih-Cheng Pao, Yu-Chuan Teng, Chun-Bing Chen, Angel Chao, Wen-Hung Chung, John Wen-Cheng Chang, Chyong-Huey Lai
Publikováno v:
Biomedicine & Pharmacotherapy, Vol 169, Iss , Pp 115928- (2023)
Neoantigen-reactive cytotoxic T lymphocytes play a vital role in precise cancer cell elimination. In this study, we demonstrate the effectiveness of personalized neoantigen-based T cell therapy in inducing tumor regression in two patients suffering f
Externí odkaz:
https://doaj.org/article/bad26cd210654a5bb7eb4d83a3412e3b
Autor:
Fur-Hsing Wen, Wen-Chi Chou, Po-Jung Su, Ming-Mo Hou, Wen-Chi Shen, Mei Huang Hsu, Siew Tzuh Tang
Publikováno v:
BMC Palliative Care, Vol 21, Iss 1, Pp 1-14 (2022)
Abstract Background/purpose The purpose of this secondary-analysis study was to identify never-before-examined factors associated with distinct depressive-symptom trajectories among family caregivers from end-of-life caregiving through the first 2 be
Externí odkaz:
https://doaj.org/article/5adf5fd3aeac4414af1b930153b1566d
Autor:
Zhenggang Ren, Michel Ducreux, Ghassan K. Abou-Alfa, Philippe Merle, Weijia Fang, Julien Edeline, Zhiwei Li, Lihua Wu, Eric Assenat, Sheng Hu, Lorenza Rimassa, Tao Zhang, Jean-Frédéric Blanc, Hongming Pan, Paul Ross, Chia-Jui Yen, Albert Tran, Guoliang Shao, Mohamed Bouattour, Yajin Chen, Tim Meyer, Jinlin Hou, David Tougeron, Yuxian Bai, Ming-Mo Hou, Zhiqiang Meng, John Wu, Vincent Li, Sandra Chica-Duque, Ann-Lii Cheng
Publikováno v:
Liver Cancer (2022)
Introduction: Tislelizumab (anti-programmed cell death protein 1 antibody) showed preliminary antitumor activity and tolerability in patients with advanced solid tumors, including hepatocellular carcinoma (HCC). This study aimed to assess the efficac
Externí odkaz:
https://doaj.org/article/5702df6d3dcb4d41bb1056d2e8bdf177
Autor:
Xiaobin Zhang, Ben M. Eyck, Yang Yang, Jun Liu, Yin-Kai Chao, Ming-Mo Hou, Tsung-Min Hung, Qingsong Pang, Zhen-Tao Yu, Hongjing Jiang, Simon Law, Ian Wong, Ka-On Lam, Berend J. van der Wilk, Ate van der Gaast, Manon C. W. Spaander, Roelf Valkema, Sjoerd M. Lagarde, Bas P. L. Wijnhoven, J. Jan B. van Lanschot, Zhigang Li
Publikováno v:
BMC Cancer, Vol 20, Iss 1, Pp 1-11 (2020)
Abstract Background After neoadjuvant chemoradiotherapy (nCRT) for esophageal cancer, high pathologically complete response (pCR) rates are being achieved especially in patients with squamous cell carcinoma (SCC). An active surveillance strategy has
Externí odkaz:
https://doaj.org/article/2843509b1b4946d9b515bcdbaadad6c4
Autor:
Wing-Keen Yap, Ming-Chieh Shih, Yu-Chen Chang, Chia-Hsin Lin, Shih-Ming Huang, Tsung-You Tsai, Ching-Fu Chang, Chih-Chung Hsu, Chen-Kan Tseng, Miao-Fen Chen, Din-Li Tsan, Chi-Ting Liau, Ming-Mo Hou, Yin-Kai Chao, Chien-Hung Chiu, Tsung-Min Hung
Publikováno v:
Biomedicines, Vol 10, Iss 11, p 2989 (2022)
Background: The prognosis of patients with resected esophageal squamous cell carcinoma after neoadjuvant chemoradiotherapy is particularly poor in those who were staged as ypT3/T4 and/or ypN+. This study investigated whether adjuvant chemoradiotherap
Externí odkaz:
https://doaj.org/article/14e526ae29d541cb94ad37bbd028f3e0
Autor:
Xing Gao, Osbert Qi-Yao Leow, Chien-Hung Chiu, Ming-Mo Hou, Jason Chia-Hsun Hsieh, Yin-Kai Chao
Publikováno v:
Journal of Personalized Medicine, Vol 12, Iss 9, p 1440 (2022)
Background: A “surgery as needed” approach may be offered to patients with esophageal cancer (EC) who achieve major histopathological response (MaHR) after neoadjuvant chemoradiotherapy (nCRT). However, the utility of clinical response assessment
Externí odkaz:
https://doaj.org/article/a7004bd56b1f4677aa5f2b758f30a39f
Autor:
Tommy Nai-Jen Chang, Ming-Mo Hou, Mohamed AbdelRahman, Chih-Wei Wang, Li-Jen Wang, Dennis S Kao, Shao-Chih Hsu, Soo-Ha Kwon, Shih-Yin Huang, John Wen-Cheng Chang, Chih-Hung Lin
Publikováno v:
Formosan Journal of Surgery, Vol 52, Iss 4, Pp 127-132 (2019)
Background: Desmoid tumor and leiomyoma are abdominal wall tumors with similar clinical, radiographic, and histological features. However, differentiation between these two diseases is important because each may be linked to different systemic diseas
Externí odkaz:
https://doaj.org/article/3c35537359fe4a55a4ac99d0f772c848
Autor:
John Chang, Chiao-En Wu, Cheng-Hsun Chiu, Ming-Mo Hou, Chih-Yu Tsai, Yu-Fen Lin, Yuan-Ming Yeh, Yung–Chi Shen, Jia-Juan Hsieh
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss Suppl 3 (2020)
Externí odkaz:
https://doaj.org/article/8124275c2b7f46e3a77ae954c8d1e567
Autor:
Yun Zhang, Xin Li, Hongming Pan, Yoon-Koo Kang, Chia-Jui Yen, Ming-Mo Hou, Kun-Ming Rau, Ying Yuan, Xiaopeng Ma, Xikun Wu, Jong-Seok Lee, Cunjing Yu, Katie Wood
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss Suppl 3 (2020)
Externí odkaz:
https://doaj.org/article/535c95318305473282560c0ef50dded5
Autor:
Bhumsuk Keam, Jayesh Desai, Ben Markman, Michael Millward, Yoon-Koo Kang, Chia-Chi Lin, Yee Chao, Sanjeev Deva, Jong Seok Lee, Chia-Jui Yen, Michael Jameson, Ming-Mo Hou, Chang-Hsien Lu, Kun-Ming Rau, Kyung-Hun Lee, Lisa Horvath, Michael Friedlander, Paula Barlow, Chi-Yuan Wu, Liang Liang, John Wu, Virginia Paton
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss 1 (2020)
Background The programmed cell death-1/programmed cell death ligand-1 (PD-1/PD-L1) axis plays a central role in suppressing antitumor immunity; axis dysregulation can be used by cancer cells to evade the immune system. Tislelizumab, an investigationa
Externí odkaz:
https://doaj.org/article/1f2f609e135d4807be9e954535daa4f0